RECORD 2017.

Methods	Design: open‐label RCT Duration: 28 August 2012 to 23 February 2015. Follow up: 12 months
Participants	Setting: multicentre (7 centres) Countries: Korea Kidney transplant recipients DD or LRD; > 20 years Number (group 1/group 2): 151 (76/75) Mean age ± SD (years): group 1 (46.1 ± 13.0); group 2 (46.0 ± 10.8) Sex (M/F): group 1 (57/21); group 2 (53/22) Exclusions: multi‐organ recipients or a kidney donated after cardiac death; ATG induction; desensitisation pre‐transplantation; identical HLA matching between donor and recipient; cold ischaemic time of > 30 hours; leukocyte count < 2500/L, neutrophil count < 1500/L or platelet count < 100,000/L; recipient with HBV or HCV infection; history of any cancer, except successfully treated localized non‐ melanoma skin cancer; ABO‐incompatible transplants.
Interventions	Treatment group 1 SRL: 2 mg within 24 hours of reperfusion; levels 3 to 5 ng/mL ER‐TAC: LRD 0.2 mg/kg 2 days before transplant. DD 0.1 mg /kg on day of transplant. Levels 3 to 12 ng/mL 1st month, then 3 to 8 ng/mL; commenced within 48 hours of transplant Treatment group 2 MMF: 500 mg within 24 hours of reperfusion; 1000 mg to 2000 mg/d ER‐TAC: LRD 0.2 mg/kg 2 days before transplant. DD 0.1 mg /kg on day of transplant. Levels 3 to 12 ng/mL 1st month, then 3 to 8 ng/mL; commenced within 48 hours of transplant Co‐interventions Basiliximab: 20 mg Prednisolone
Outcomes	Efficacy failure BPAR Graft loss Patient death/patient loss to follow‐up eGFR (MDRD) Overall survival and graft survival
Notes	Comparison TOR‐I versus antimetabolite
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomization was centrally released by an electronic case report form before transplantation. Randomization code was generated and performed using a block designed stratified by each site"
Allocation concealment (selection bias)	Low risk	Quote: "randomization was centrally released by an electronic case report form before transplantation. Randomization code was generated and performed using a block designed stratified by each site"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	All blinded before randomisation
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome BPAR, graft loss and patient death and unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	All patients accounted for but greater than 10% not analysed
Selective reporting (reporting bias)	Low risk	All pre‐specified outcomes mentioned
Other bias	High risk	Pharma funded study. Funded by Astellas